ICD-9: 277.31. Short Description: Fam Mediterranean fever. Long Description: Familial Mediterranean fever. This is the 2014 version of the ICD-9-CM diagnosis code 277.31.
Periodic fever syndromes. M04.1 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
There's no cure for familial Mediterranean fever. However, treatment can help relieve symptoms, prevent attacks and prevent complications caused by inflammation. Medications used to relieve symptoms and prevent attacks of FMF include: Colchicine.
Tests and procedures used to diagnose familial Mediterranean fever include: Physical exam. Your doctor may ask you about your signs and symptoms and conduct a physical exam to gather more information.
277.31 - Familial Mediterranean fever. ICD-10-CM.
Overview. Familial Mediterranean fever (FMF) is a genetic autoinflammatory disorder that causes recurrent fevers and painful inflammation of your abdomen, chest and joints.
Causes. Familial Mediterranean fever is caused by variants (also known as mutations) in the MEFV gene. The MEFV gene provides instructions for making a protein called pyrin (also known as marenostrin), which is found in white blood cells.
Nearly all people with FMF start having periodic fevers before age 20. Three-quarters of people with this condition have their first episodes before age 10. All genders can get it.
A diagnosis of FMF can be confirmed by molecular genetic testing, which can identify the characteristic MEFV gene mutations that cause the disorder. Molecular genetic testing is available through commercial and academic diagnostic laboratories.
Primary Immunodeficiencies FMF is an autosomal recessive disease that occurs preferentially in people of Middle Eastern ethnic backgrounds. FMF is caused by mutations in an inflammatory regulator called marenostrin (or pyrin), which is expressed almost exclusively by activated monocytes and granulocytes.
Initial treatment of FMF is with colchicine. Colchicine — Colchicine is primarily effective as a prophylactic treatment for the FMF attacks. It is recommended in all patients regardless of the frequency and intensity of attacks.
It is characterized by recurrent bouts of fever, appendicitis-like stomach pain, lung inflammation, and swollen, painful joints. As a chronic, recurrent disorder, FMF can cause short-term disability and significantly impair a person's quality of life.
Similarly, different manifestations of FMF have been observed among populations of various ethnic origins. However, attacks generally tend to decrease with aging in most FMF patients. Each attack lasts 1-4 days on average and resolves spontaneously.
This study has shown that fatigue in FMF is associated with a number of psychological, sleep, quality of life and disease-related factors. FMF group had increased pain, fatigue, sleep disturbance and decreased quality of life compared to control group.
Four FMF patients suffered from lower back pain, although none of them had spinal involvement. On the other hand, approximately one third of juvenile SpA patients had spinal involvement.